Compare Expensify Inc (EXFY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs TG Therapeutics Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 39.1× Expensify Inc's market cap, and Expensify Inc is more actively traded (456,102 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and TG Therapeutics Inc for 16 Days on average.
| EXFY | TGTX | |
|---|---|---|
Market Cap | $208.82M | $8.16B |
Volume | 456,102 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $2.72 | $59.06 |
52-Week Low | $0.75 | $26.94 |
Typical Hold Time | 41 Days | 16 Days |
Enterprise Value | $148.44M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% today, showing technical bullish momentum with positive moving average signals. The company reported mixed Q2 2026 results with revenue of $33.9M and improved profitability, beating EPS estimates. Recent developments include AI-native ERP integrations and European card expansion, though fundamentals show negative net margins and high P/E ratio of 258.82. Analyst consensus is bullish with a $13.75 price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with strong analyst optimism contrasting with fundamental challenges. The stock's substantial discount to consensus target offers potential upside, but investors must weigh improving cash flow trends against persistent negative profitability and competitive pressures in the expense management sector.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
